Search

Race Oncology

Article Timeline

Notable People

NamePositionYear Started
Peter Molloy
Peter Molloy *
Managing Director2016
Peter Webse
Peter Webse
Company Secretary2016
William Garner
William Garner
Non-Executive Chairman2016
Chris Ntoumenopoulos
Chris Ntoumenopoulos
Non-Executive Director2016
John Cullity
John Cullity
Non-Executive Director2018
Samar Al-Behaisi
Samar Al-Behaisi
Chief Medical Officer, Vice President of Medical Affairs2018
* Most Senior WA Executive

Past Employees

NamePositionYear StartedYear Ended
Brendan de Kauwe Non-Executive Director20162018
John Rothman Consultant (Sept-Dec 2018); (Chief Scientific Officer 2016-Aug 2018)20162018
Ananda Kathiravelu Director2016

ECM Deals

DateCompanyTransaction TypeTotal Value
12/03/18Race OncologyPlacement$3.6m>>
17/07/17Race OncologyPlacement$2.5m>>

M&A Deals

AnnouncedBidderTargetTransaction TypeTotal Value
11/04/16Coronado ResourcesRace OncologyReverse takeover$3.0m>>

Biography

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage assets, principally in the cancer field. The company's first important asset is a chemotherapy drug called Bisantrene, which was the subject of more than 40 phase II clinical studies in the 1980s and 1990s. The company was formed when unlisted Perth company Coronado Resources acquired US-based biotech company Update Pharma, which owned the technology relating to Bisantrene. As part of the acquisition process Coronado launched a successful IPO to list on the ASX as Race Oncology.
Biography last updated 06 Mar 2019

Share Transactions

08/02/19
$0 Other
08/02/19
$0 Other
08/02/19
$0 Other
Total value as at the date of the transaction
Source: Morningstar

BNiQ Disclaimer